AstraZeneca completed the acquisition of Neogene Therapeutics from Syncona for $320m.

AstraZeneca, a biopharmaceutical company, completed the acquisition of Neogene Therapeutics, an operator of a preclinical stage biotechnology company, from Syncona, a healthcare company focused on investing in and building global firms in life science, for $320m. “This acquisition represents a unique opportunity to bring innovative science and leading experts in T-cell receptor biology and cell therapy manufacturing together with our internal oncology cell therapy team, unlocking new ways to target cancer. Neogene’s leading TCR discovery capabilities and extensive manufacturing experience complement the cell therapy capability we have built over the last three years and allow us to accelerate the development of potentially curative cell therapies for the benefit of patients," Susan Galbraith, AstraZeneca Executive Vice President of Oncology R&D.